

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce the launch of *Alma TED™* ^(Note 1) and *CBD+ Professional Skincare Solution™* (the “**Products**”) for the U.S. Market.

Alma TED™ is an ultrasound-based system with a propriety tip engineered with *Impact Delivery™* that offers a non-invasive, non-traumatic option to address the market’s growing hair loss concerns. *Impact Delivery™* is a patented ultrasound technology using acoustic pressure to deliver pharmaceuticals and cosmeceuticals trans-epidermally to achieve enhanced results.

CBD+ Professional Skincare Solution™ is the first professional skincare solution that combines the scientific benefits of full-spectrum cannabidiol (CBD), shown to visibly reduce redness and calm the appearance of stressed skin, with clinically proven cosmetic ingredients to visibly rebalance the skin back to a natural and healthy state.

The Company believes that the launch of the Products will strengthen the Company’s product portfolio and product competitiveness and will also improve the recurring revenues from consumables of the Company.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, March 25, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non – executive Directors.

* *for identification purpose only*

Note 1: Class 1 medical device pending clearance of the Food and Drug Administration of the United States.